Probiotics have shown promising therapeutic effects against colibacillosis. Bacillus clausii is a spore-forming Gram-positive bacterium with the unique ability to produce endospores that withstand harsh conditions such as gastric acid and bile salts, allowing it to exert probiotic and antimicrobial effects. This study aimed to evaluate the probiotic potential of B. clausii and investigate its therapeutic impact on Escherichia coli-induced diarrhea in rats, focusing on body weight, lipid profile, and protein parameters. The experiment was conducted on 15 albino Sprague-Dawley rats, randomly assigned to three groups: G1 (healthy control), G2 (infected with E. coli), and G3 (infected with E. coli and treated with B. clausii). The study measured body weight, lipid levels, and protein concentrations in all groups. The results revealed a significant (P < 0.05) increase in body weight in the treated group (G3), reaching 266.3 g with a weight gain of 90.0 g, compared to the infected and control groups. Lipid profile analysis showed reductions in cholesterol (CHOL), triglycerides (TG), LDL, and HDL levels to 64.5, 54.6, 12.13, and 36.5 mg/dL, respectively, in G3, compared to G1 (73.4, 94.0, 16.4, and 38.9 mg/dL) and G2 (74.0, 96.8, 18.4, and 17.4 mg/dL). Total protein and albumin levels were significantly (P < 0.05) higher in the treated group compared to G1 and G2. In conclusion, Bacillus clausii treatment significantly improved physiological parameters in E. coli-infected rats, highlighting its therapeutic potential. Further studies are recommended to explore its benefits across other health indicators.
Keywords | Bacillus clausii, Escherichia coli, Blood protein values, Lipid profile, Probiotics, Sprague–Dawley